DBV Technologies SA (DBVT)
0.6669
0.00 (0.00%)
USD |
NASDAQ |
May 03, 16:00
0.662
0.00 (0.00%)
After-Hours: 20:00
DBV Technologies SG&A Expense (Quarterly): 6.443M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 6.443M |
September 30, 2023 | 4.244M |
June 30, 2023 | 6.951M |
March 31, 2023 | 5.24M |
December 31, 2022 | 5.461M |
September 30, 2022 | 2.75M |
June 30, 2022 | 5.282M |
March 31, 2022 | 4.168M |
December 31, 2021 | 2.917M |
September 30, 2021 | 5.87M |
Date | Value |
---|---|
June 30, 2021 | 5.747M |
March 31, 2021 | 6.782M |
December 31, 2020 | 7.209M |
September 30, 2020 | 4.829M |
June 30, 2020 | 4.803M |
March 31, 2020 | 18.41M |
December 31, 2019 | 19.58M |
September 30, 2019 | 12.32M |
December 31, 2018 | 23.70M |
September 30, 2018 | 23.17M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.75M
Minimum
Sep 2022
19.58M
Maximum
Dec 2019
7.167M
Average
5.604M
Median
SG&A Expense (Quarterly) Benchmarks
Biophytis SA | -- |
Edap TMS SA | 10.60M |
Cellectis SA | 4.671M |
Genfit SA | -- |
Adaptimmune Therapeutics PLC | 16.88M |